System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective

Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a childr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2012-06, Vol.34 (6), p.1459-1465
Hauptverfasser: Nichols, Kristen R., PharmD, BCPS, Knoderer, Chad A., PharmD, Cox, Elaine G., MD, Kays, Michael B., PharmD, FCCP
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1465
container_issue 6
container_start_page 1459
container_title Clinical therapeutics
container_volume 34
creator Nichols, Kristen R., PharmD, BCPS
Knoderer, Chad A., PharmD
Cox, Elaine G., MD
Kays, Michael B., PharmD, FCCP
description Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.
doi_str_mv 10.1016/j.clinthera.2012.05.005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020508701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291812003232</els_id><sourcerecordid>2747491841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</originalsourceid><addsrcrecordid>eNqNks9u1DAQxiMEokvhFcASQnDJduzE-dMDUrV06UqVqLRdwc1ynEnrJXGC7a1In4jHxNEurdQT8sE-_Oabz_NNFL2jMKdAs5PtXLXa-Fu0cs6AsjnwOQB_Fs1okZcxpemP59EMaFrGrKTFUfTKuS0AJCVnL6MjxjKeM57Moj_r0Xns4u-6RrLqhhY7NF563RvSNyR0IBuH01Macv7bo6mxjlem2bkJudJDsKB0G9ycXMv7vpLKy4586Z02N2TtrfR4M56SJUqnK91qP05iGx-e9_s2S9t3RJLFrW5ri-ajIxe9G7SXLblC6wZUXt_h6-hFI1uHbw73cbRZnl8vLuLLb19Xi7PLWPEk8XGlQJZJURR1URUU8iatG5lDljecKWwwK5WqKp5AWkle8YqBgiyTeUrTgtKmSI6jT3vdwfa_dui86LRT2LbSYL9zggIDDkUONKDvn6DbfmdNcBeoJMuSEtJJMN9TyvbOWWzEYHUn7RggMYUptuIhTDGFKYCLEGaofHvQ31Ud1g91_9ILwIcDIJ2SbWOlUdo9chnQvGSThbM9h2FwdxqtcEqjUVhrG6Yr6l7_h5nPTzQmToe2P3FE9_hz4UKNWE-7N60eZWHrWDh_AVBG2MY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1036639048</pqid></control><display><type>article</type><title>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Nichols, Kristen R., PharmD, BCPS ; Knoderer, Chad A., PharmD ; Cox, Elaine G., MD ; Kays, Michael B., PharmD, FCCP</creator><creatorcontrib>Nichols, Kristen R., PharmD, BCPS ; Knoderer, Chad A., PharmD ; Cox, Elaine G., MD ; Kays, Michael B., PharmD, FCCP</creatorcontrib><description>Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged &gt;30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2012.05.005</identifier><identifier>PMID: 22657253</identifier><language>eng</language><publisher>Bridgewater, NJ: Elsevier Inc</publisher><subject>Adolescent ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - therapeutic use ; Antimicrobial agents ; Bacteria ; Bacterial infections ; Biological and medical sciences ; Child ; Child, Preschool ; Children &amp; youth ; Drug stores ; extended infusion ; Feasibility Studies ; Female ; Hospitals ; Hospitals, Pediatric ; Humans ; Infant ; Internal Medicine ; Male ; Medical Education ; Medical sciences ; Monte Carlo simulation ; Mortality ; Nursing ; pediatric ; Pediatrics ; Penicillanic Acid - administration &amp; dosage ; Penicillanic Acid - analogs &amp; derivatives ; Penicillanic Acid - therapeutic use ; Pharmacology. Drug treatments ; Piperacillin - administration &amp; dosage ; Piperacillin - therapeutic use ; piperacillin-tazobactam</subject><ispartof>Clinical therapeutics, 2012-06, Vol.34 (6), p.1459-1465</ispartof><rights>Elsevier HS Journals, Inc.</rights><rights>2012 Elsevier HS Journals, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</citedby><cites>FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1036639048?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26017928$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22657253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nichols, Kristen R., PharmD, BCPS</creatorcontrib><creatorcontrib>Knoderer, Chad A., PharmD</creatorcontrib><creatorcontrib>Cox, Elaine G., MD</creatorcontrib><creatorcontrib>Kays, Michael B., PharmD, FCCP</creatorcontrib><title>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged &gt;30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.</description><subject>Adolescent</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children &amp; youth</subject><subject>Drug stores</subject><subject>extended infusion</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Hospitals</subject><subject>Hospitals, Pediatric</subject><subject>Humans</subject><subject>Infant</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Education</subject><subject>Medical sciences</subject><subject>Monte Carlo simulation</subject><subject>Mortality</subject><subject>Nursing</subject><subject>pediatric</subject><subject>Pediatrics</subject><subject>Penicillanic Acid - administration &amp; dosage</subject><subject>Penicillanic Acid - analogs &amp; derivatives</subject><subject>Penicillanic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperacillin - administration &amp; dosage</subject><subject>Piperacillin - therapeutic use</subject><subject>piperacillin-tazobactam</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNks9u1DAQxiMEokvhFcASQnDJduzE-dMDUrV06UqVqLRdwc1ynEnrJXGC7a1In4jHxNEurdQT8sE-_Oabz_NNFL2jMKdAs5PtXLXa-Fu0cs6AsjnwOQB_Fs1okZcxpemP59EMaFrGrKTFUfTKuS0AJCVnL6MjxjKeM57Moj_r0Xns4u-6RrLqhhY7NF563RvSNyR0IBuH01Macv7bo6mxjlem2bkJudJDsKB0G9ycXMv7vpLKy4586Z02N2TtrfR4M56SJUqnK91qP05iGx-e9_s2S9t3RJLFrW5ri-ajIxe9G7SXLblC6wZUXt_h6-hFI1uHbw73cbRZnl8vLuLLb19Xi7PLWPEk8XGlQJZJURR1URUU8iatG5lDljecKWwwK5WqKp5AWkle8YqBgiyTeUrTgtKmSI6jT3vdwfa_dui86LRT2LbSYL9zggIDDkUONKDvn6DbfmdNcBeoJMuSEtJJMN9TyvbOWWzEYHUn7RggMYUptuIhTDGFKYCLEGaofHvQ31Ud1g91_9ILwIcDIJ2SbWOlUdo9chnQvGSThbM9h2FwdxqtcEqjUVhrG6Yr6l7_h5nPTzQmToe2P3FE9_hz4UKNWE-7N60eZWHrWDh_AVBG2MY</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Nichols, Kristen R., PharmD, BCPS</creator><creator>Knoderer, Chad A., PharmD</creator><creator>Cox, Elaine G., MD</creator><creator>Kays, Michael B., PharmD, FCCP</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</title><author>Nichols, Kristen R., PharmD, BCPS ; Knoderer, Chad A., PharmD ; Cox, Elaine G., MD ; Kays, Michael B., PharmD, FCCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-bc0a93888d8b8107f4dfa7067f52cefe69ccbb5304ba5b5b20c066a7414811f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children &amp; youth</topic><topic>Drug stores</topic><topic>extended infusion</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Hospitals</topic><topic>Hospitals, Pediatric</topic><topic>Humans</topic><topic>Infant</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Education</topic><topic>Medical sciences</topic><topic>Monte Carlo simulation</topic><topic>Mortality</topic><topic>Nursing</topic><topic>pediatric</topic><topic>Pediatrics</topic><topic>Penicillanic Acid - administration &amp; dosage</topic><topic>Penicillanic Acid - analogs &amp; derivatives</topic><topic>Penicillanic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperacillin - administration &amp; dosage</topic><topic>Piperacillin - therapeutic use</topic><topic>piperacillin-tazobactam</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nichols, Kristen R., PharmD, BCPS</creatorcontrib><creatorcontrib>Knoderer, Chad A., PharmD</creatorcontrib><creatorcontrib>Cox, Elaine G., MD</creatorcontrib><creatorcontrib>Kays, Michael B., PharmD, FCCP</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nichols, Kristen R., PharmD, BCPS</au><au>Knoderer, Chad A., PharmD</au><au>Cox, Elaine G., MD</au><au>Kays, Michael B., PharmD, FCCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>34</volume><issue>6</issue><spage>1459</spage><epage>1465</epage><pages>1459-1465</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Abstract Background Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods This was a prospective observational study of patients aged &gt;30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.</abstract><cop>Bridgewater, NJ</cop><pub>Elsevier Inc</pub><pmid>22657253</pmid><doi>10.1016/j.clinthera.2012.05.005</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-2918
ispartof Clinical therapeutics, 2012-06, Vol.34 (6), p.1459-1465
issn 0149-2918
1879-114X
language eng
recordid cdi_proquest_miscellaneous_1020508701
source MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland
subjects Adolescent
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - therapeutic use
Antimicrobial agents
Bacteria
Bacterial infections
Biological and medical sciences
Child
Child, Preschool
Children & youth
Drug stores
extended infusion
Feasibility Studies
Female
Hospitals
Hospitals, Pediatric
Humans
Infant
Internal Medicine
Male
Medical Education
Medical sciences
Monte Carlo simulation
Mortality
Nursing
pediatric
Pediatrics
Penicillanic Acid - administration & dosage
Penicillanic Acid - analogs & derivatives
Penicillanic Acid - therapeutic use
Pharmacology. Drug treatments
Piperacillin - administration & dosage
Piperacillin - therapeutic use
piperacillin-tazobactam
title System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A31%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=System-Wide%20Implementation%20of%20the%20Use%20of%20an%20Extended-Infusion%20Piperacillin/Tazobactam%20Dosing%20Strategy:%20Feasibility%20of%20Utilization%20From%20a%20Children's%20Hospital%20Perspective&rft.jtitle=Clinical%20therapeutics&rft.au=Nichols,%20Kristen%20R.,%20PharmD,%20BCPS&rft.date=2012-06-01&rft.volume=34&rft.issue=6&rft.spage=1459&rft.epage=1465&rft.pages=1459-1465&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2012.05.005&rft_dat=%3Cproquest_cross%3E2747491841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1036639048&rft_id=info:pmid/22657253&rft_els_id=S0149291812003232&rfr_iscdi=true